When selecting and qualifying the primary packaging for lyophilized drug products, an essential question arises: How comprehensive should the extractables and leachables qualification process for a lyophilization container be? This question is particularly relevant given that lyophilized drug products are in a solid state, which theoretically minimizes interactions between the drug product and the container components. This assumption is supported by guidelines such as the USP <1664> Monograph on Leachables and the EMA Guideline on “Plastic Immediate Packaging Materials” (2005).
Despite this expectation of low interaction, the mechanism by which lyophilized drug products, or lyo-cakes, interact with the rubber stoppers of lyophilization vials is not fully understood. The interaction primarily occurs through the outgassing of volatile and semi-volatile compounds from the rubber stopper, with the lyo-cake acting as an adsorbent. This adsorption can lead to a significant accumulation of leachable compounds on the lyophilized drug product. More concerning is the potential for these leachables to induce chemical reactions with the drug product, particularly if the leachables possess electrophilic properties.
This webinar will provide an in-depth explanation of the outgassing mechanism from lyo-stoppers and how it contributes to the accumulation of leachables on the lyo-cake. Understanding this mechanism is crucial for developing effective strategies to mitigate these interactions and ensure the stability and safety of lyophilized drug products.
Additionally, the webcast will introduce an experimental testing strategy designed to address these concerns comprehensively. This strategy includes the discovery, identification, and quantification of leachables, as well as monitoring the formation of secondary leachables that result from chemical reactions between the primary leachables and the drug product ingredients. By identifying and quantifying these interactions, manufacturers can better understand the potential risks and implement measures to control and minimize them.
The insights provided in this webcast will help manufacturers ensure that their lyophilized drug products meet regulatory requirements and maintain their integrity throughout their shelf life. Participants will gain a clear understanding of how to approach the extractables and leachables qualification process for lyophilization containers, ensuring both compliance and the safety of their drug products.
Title Tag: The New FDA Draft Guidance for Biocompatibility of Certain Devices in Contact with Intact Skin | Sotera
Description Tag: This webinar will provide a comprehensive examination of the new FDA draft biocompatibility guidance, offering insights into its implications for skin-contacting medical devices.